Deeper molecular responses were significantly associated with better OS, similar to the differential rates of OS observed when patients were segregated according to cytogenetic responses achieved on therapy. OS and progression-free survival (PFS) comparison between CCyR vs no CCyR in both the dasatinib and imatinib arms were significant, as was major molecular response (MMR) vs no MMR. Ph⁺ indicates the number of Philadelphia-positive metaphases in a BM cytogenetic preparation by G-banding; DAS 100, dasatinib 100 mg once daily; IM 400, imatinib 400 mg once daily; NIL 300, nilotinib 300 mg BID; and ?, values not published.

*Statistically significant comparison between BCR-ABL > 10% and ≤ 10% at P < .05.

†Statistically significant comparison between BCR-ABL > 1% and ≤ 1% at P < .05.

‡Statistically significant comparison between Ph⁺ > 35% and ≤ 35% at P < .05.

§Statistically significant comparison between CCyR vs no CCyR at P < .05.